At #ESMO26 we spoke with Ari Rosenberg (@UCCancerCenter) who discussed emerging strategies for recurrent/metastatic head and neck cancer, including the frontline carboplatin-amivantamab-pembrolizumab triplet now being tested against standard chemoimmunotherapy in an ongoing Phase III trial.

🎥 https://tinyurl.com/3zfbtda8

#HNSCC #HeadandNeckCancer @myESMO